Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2012

uniQure and Benitec Enter Cross-Licensing Agreement

  • uniQure entered a nonexclusive cross-licensing agreement with Benitec Biopharma giving uniQure access to Benitec’s DNA-directed RNA interference (ddRNAi) technology in Huntington’s disease. In return, uniQure granted Benitec nonexclusive access to the company’s AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B.

    “While our current programs focus on delivering fully functioning therapeutic genes to remedy faulty or malfunctioning genes, Benitec’s ddRNAi technology will allow us to do the opposite—to silence the gene responsible for producing the mutant protein that lies at the basis of Huntington’s disease, and to develop a therapy for this devastating disease,” said Jörn Aldag, CEO of uniQure.

    uniQure focuses on the development of human gene-based therapies. The company achieved market approval by European Commission for a gene therapy product, Glybera, for the treatment of lipoprotein lipase deficiency. Glybera is the first approved gene therapy in the Western world.

    In June, uniQure collaborated with UCSF on the company’s glial cell-derived neurotrophic factor gene for the treatment of Parkinson’s disease.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »